SpectraWAVE, Inc. | LinkedIn (original) (raw)

Medical Equipment Manufacturing

Bedford, MA 6,670 followers

Improving coronary artery disease outcomes with optical and computational insights.

View all 52 employees

About us

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

Industry

Medical Equipment Manufacturing

Company size

11-50 employees

Headquarters

Bedford, MA

Type

Privately Held

Locations

Employees at SpectraWAVE, Inc.

Updates

SpectraWAVE, Inc. reposted this
SpectraWAVE, Inc. (#LSIAlumni) raised a $50 million Series B funding round led by Johnson & Johnson Innovation - JJDC, Inc., with participation from S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture, Heartwork Capital, and undisclosed parties. LSI events have played an instrumental role in SpectraWAVE’s fundraising journey, illustrated by CEO, Eman Namati: "LSI USA '24 was an outstanding experience for us and, without a doubt, the best Medtech investor event I’ve attended. The media exposure from our presentation, combined with the exceptional environment for networking and sharing our story, had a meaningful and positive impact on our fundraising efforts." The funding will support the commercial expansion and new product developments for the company’s 510(k)-cleared HyperVue™ Imaging System. Congratulations to the many LSI Alumni involved in this financing, including teams from Johnson & Johnson Innovation - JJDC, SV Health Investors, and Deerfield Management. We look forward to hearing more from Eman Namati next week at LSI Europe '24, where he’ll be speaking on the panel, "Light at the End of the Tunnel in Medtech Financing", alongside Nick Pachuda, Martin Omid A., Anita Watkins, and Sean Morris.
We’re thrilled to announce a successful $50M Series B financing led by Johnson and Johnson Innovation – JJDC, Inc. and joined by a number of leading MedTech investors including S3 Ventures, Lumira Ventures, SV Health Investors, and Deerfield Management. This new funding will support commercial expansion of our AI enabled FDA-cleared intravascular imaging solution, the HyperVue Imaging System, as well as our in-development wire-free physiology technology. This funding comes at a pivotal time in the imaging space as evidence continues to grow and recently released European guidelines now cite intravascular imaging as a 1A recommendation for supporting PCI of complex lesions. We’re excited about what’s next. Big things are on the horizon for SpectraWAVE and coronary care! Learn more here: https://lnkd.in/edtWFzyn #ImageFirst
📢 Breaking News: Intravascular Imaging Now Class IA Recommendation for Europe! Updated 2024 Guidelines presented today at ESC Congress now recommend imaging as Class IA for complex PCI! This is a testament to the value of imaging for clinicians and their patients and we are excited to play our part with HyperVue.
Congratulations to OPCI for their 10th New York meeting! It was a privilege to participate in and support their promotion of training and innovation in the interventional cardiology community. We're excited to see how the HyperVue Imaging System and #DeepOCT+NIRS can play a part.
Thank you to Dr. Ziad Ali for his presentation of DeepOCT+NIRS in the Best of JSCAI Session at SCAI 2024. Learn more by visiting the SpectraWAVE team at SCAI 2024 booth #411 to see a demo, or visiting our website http://spectrawave.com!
Join us next week in Long Beach for SCAI 2024! Come by booth 411 for a demo of the HyperVue Imaging System and see the value of DeepOCT+NIRS. Also, be sure to mark your calendars for the Best of JSCAI session on 5/2 to learn about the latest clinical publication!
Thrilled to share our CEO Eman Namati presenting SpectraWAVE’s HyperVue Imaging System and the unique value of our #DeepOCT+NIRS technology for simple, fast and effective coronary stent planning and optimization. #LSIUSA24
Eman Namati, SpectraWAVE - AI-Enabled Intravascular Imaging | LSI USA '24

https://www.youtube.com/

📣 New Publication out now in JSCAI highlighting clinical experience and unique value of the HyperVue Imaging System, SpectraWAVE’s intravascular imaging platform! The publication showcases DeepOCT+NIRS imaging in various plaque morphologies, and head-to-head image comparisons to other commercial products. Congratulations to all the authors! Read the full publication here: https://lnkd.in/ekrNK6QX

Join now to see what you are missing

Join now

SpectraWAVE, Inc. | LinkedIn (original) (raw)

Medical Equipment Manufacturing

Bedford, MA 6,670 followers

Improving coronary artery disease outcomes with optical and computational insights.

About us

Locations

Employees at SpectraWAVE, Inc.

Updates

https://www.youtube.com/

Join now to see what you are missing

Similar pages

Browse jobs

Funding